TransMedics Group, Inc. (BMV:TMDX)
Mexico · Delayed Price · Currency is MXN | Market Cap | 44.33B -36.2% |
| Revenue (ttm) | 11.46B +30.2% |
| Net Income | 3.10B +251.2% |
| EPS | 80.46 +216.8% |
| Shares Out | n/a |
| PE Ratio | 14.30 |
| Forward PE | 30.99 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 42 |
| Open | 1,284.30 |
| Previous Close | 1,299.85 |
| Day's Range | 1,284.30 - 1,284.30 |
| 52-Week Range | 1,050.00 - 2,662.00 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 31, 2026 |
About TransMedics Group
TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung tra... [Read more]
Financial Performance
In 2025, TransMedics Group's revenue was $605.49 million, an increase of 37.13% compared to the previous year's $441.54 million. Earnings were $190.29 million, an increase of 436.58%.
Financial numbers in USD Financial StatementsNews
TransMedics to Report Second Quarter 2026 Financial Results on August 4, 2026
ANDOVER, Mass., July 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-s...
TransMedics price target lowered to $90 from $100 at Evercore ISI
Evercore ISI analyst Daniel Markowitz lowered the firm’s price target on TransMedics (TMDX) to $90 from $100 and keeps an Outperform rating on the shares. The firm’s Q2 preview for…
TransMedics completes strategic investment in PAD Aviation
TransMedic announced the closing of its strategic investment in PAD Aviation, a Germany-based private aviation operator. The investment in PAD Aviation is a “critical step forward” for TransMedics (TM...
TransMedics Group Announces Completion of Strategic Investment in PAD Aviation service GmbH
Strategic investment in Germany-based PAD Aviation, a premier European private aviation operator, lays the foundation for TransMedics to establish a dedicated organ transplantation air logistics netwo...
TransMedics benefiting from growth in heart transplant volumes, says TD Cowen
Monthly U.S. transplant tracking indicates that TransMedics (TMDX) is benefiting from continued growth in heart, liver, and lung transplant volumes, which rose about 5% year over year in Q2 and…
TransMedics price target raised to $80 from $75 at Stifel
Stifel raised the firm’s price target on TransMedics (TMDX) to $80 from $75 and keeps a Hold rating on the shares. Strengthening flight data points to a “solid” Q2 top-line…
Johnson Fistel Investigates TransMedics Group, Inc. (TMDX) After Recent Disclosures Concerning Margin Pressure and NOP Investments
SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating TransMedics Group, Inc. (NASDAQ: TMDX) on behalf of investors who suffered losses and whether those losses may be rec...
TransMedics Group Transcript: 46th Annual William Blair Growth Stock Conference
A transformative organ care system and vertically integrated logistics network have driven record organ utilization and double-digit growth, with ambitious targets to expand U.S. and global transplants through new technology and international partnerships. Focus remains on innovation, operational scale, and clinical excellence.
TransMedics price target lowered to $75 from $85 at Stifel
Stifel analyst Thomas Stephan lowered the firm’s price target on TransMedics (TMDX) to $75 from $85 and keeps a Hold rating on the shares. After having spoken with four U.S.
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
ANDOVER, Mass., May 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...
TransMedics to Present at the William Blair 46th Annual Growth Stock Conference
ANDOVER, Mass., May 19, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-st...
TransMedics Group Proxy statement: Proxy filing
TransMedics Group filed a proxy statement on May 7, 2026, providing details for shareholder voting and corporate governance matters.
TransMedics downgraded to Perform from Outperform at Oppenheimer
Oppenheimer downgraded TransMedics (TMDX) to Perform from Outperform without a price target post the Q1 report. The cites “pure exhaustion defending this name” for the downgrade. The clinical value pr...
TransMedics price target lowered to $140 from $157 at Baird
Baird analyst David Rescott lowered the firm’s price target on TransMedics (TMDX) to $140 from $157 and keeps an Outperform rating on the shares. The firm updated its model following…
TransMedics price target lowered to $85 from $130 at Stifel
Stifel analyst Thomas Stephan lowered the firm’s price target on TransMedics (TMDX) to $85 from $130 and keeps a Hold rating on the shares.
TransMedics price target lowered to $124 from $152 at Canaccord
Canaccord analyst William Plovanic lowered the firm’s price target on TransMedics (TMDX) to $124 from $152 and keeps a Buy rating on the shares. The firm said they released a…
TransMedics price target lowered to $120 from $190 at TD Cowen
TD Cowen analyst Joshua Jennings lowered the firm’s price target on TransMedics (TMDX) to $120 from $190 and keeps a Buy rating on the shares. The firm said its Q1…
TransMedics price target lowered to $142 from $174 at Needham
Needham lowered the firm’s price target on TransMedics (TMDX) to $142 from $174 and keeps a Buy rating on the shares. The company’s Q1 revenue and earnings missed consensus estimates,…
TransMedics falls -20.5%
TransMedics (TMDX) is down -20.5%, or -$19.43 to $75.50.
TransMedics Group Earnings Call Transcript: Q1 2026
Q1 2026 delivered 21% revenue growth and strong operational execution, despite regulatory headwinds and donor supply volatility. Major investments in technology, logistics, and international expansion support a reiterated 2026 revenue guidance of $727–$757 million.
TransMedics Group Earnings release: Q1 2026
TransMedics Group released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
TransMedics Group Quarterly report: Q1 2026
TransMedics Group has published its Q1 2026 quarterly earnings report on May 5, 2026.
TransMedics Group Slides: Q1 2026
TransMedics Group has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
TransMedics Reports First Quarter 2026 Financial Results
ANDOVER, Mass., May 5, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-sta...